new
   Selpercatinib(Retevmo) Instructions, Medicare, Price, Efficacy, Side Effects
500
Jun 30, 2025

With the deepening of medical research, the indications and medication regimens of Selpercatinib are also being optimized. In the future, Selpercatinib is expected to become a treatment option for more patients with specific diseases and contribute more to the treatment of diseases. So, what are the instructions, medical insurance, price, efficacy, and side effects of Selpercatinib for Retevmo?

Selpercatinib(Retevmo) Instructions, Medicare, Price

The following is about Selpercatinib(Retevmo) instructions, medical insurance, and price introduction:

Instruction Manual

Selpercatinib is a capsule drug that is mainly used for the treatment of RET fusion-positive non-small cell lung disease, RET mutant medullary thyroid disease, etc. The recommended dosage is adjusted according to body weight and should be swallowed whole, avoiding crushing or chewing. There may be some side effects associated with the medication. Before use, patients should read the instructions carefully and use under the guidance of a doctor.

Medical insurance

At present, Selpercatinib has not been included in the Chinese medical insurance list. This means that when a patient buys the drug in a hospital or pharmacy, it cannot be reimbursed directly through Medicare and needs to bear the full cost of it.

Price

The price of Selpercatinib varies depending on the manufacturer, specifications, and purchase channel. The Laos Lucius version is a 40mg 120-capsule capsule; The Bangladesh Everest version of 40mg 30 capsules.

Selpercatinib is an important therapeutic drug, and it is necessary to fully understand its label information before use, and pay attention to medical insurance and price in order to make reasonable treatment decisions.

Efficacy, side effects, and side effects of Selpercatinib(Retevmo)

The following is about the efficacy and side effects of Selpercatinib(Retevmo):

Efficacy

Selpercatinib is a highly effective therapeutic drug that is primarily used to treat RET fusions or mutation-positive diseases. By inhibiting RET kinase and its downstream signaling pathway, Selpercatinib can effectively inhibit the growth and spread of diseased cells, thereby prolonging the survival and improving the quality of life of patients.

Side effects

Although Selpercatinib excels in the treatment of the disease, it can also trigger some side effects. Common side effects include edema, diarrhea, high blood pressure, etc., which are usually mild and manageable. There may also be some serious side effects, such as hepatotoxicity, QT interval prolongation, etc., which may pose a greater health threat to patients.

When using Selpercatinib, patients need to pay close attention to their body reactions, and regularly monitor liver function, lung condition, etc., to ensure that possible side effects are detected and treated in a timely manner.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Selpercatinib(Retevmo)
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion.
RELATED ARTICLES
What are the precautions for the use of Selpercatinib(Retevmo)?

As an oral targeted drug, Selpercatinib is easy to use and has high patient compliance. By inhibiting RET...

Monday, June 30th, 2025, 17:25
Are the adverse effects of Selpercatinib(Retevmo) serious?

Selpercatinib(Retevmo) is a targeted drug that has demonstrated significant efficacy in the treatment of...

Monday, June 30th, 2025, 17:17
The treatment effect of Selpercatinib(Retevmo)

Since its approval, the drug, developed by Eli Lilly and Company, has become one of the preferred treatments for...

Monday, June 30th, 2025, 17:04
How to use Selpercatinib(Retevmo)?

Selpercatinib is not only effective in the treatment of RET fusion-positive non-small cell lung disease and...

Monday, June 30th, 2025, 16:43
RELATED MEDICATIONS
Adagrasib
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...
TOP
1
Selpercatinib
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC)...
TOP
2
Mobocertinib
Adult patients with locally advanced or metastatic non-small cell lung cancer...
TOP
3
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved